[Doripenem: need for a new carbapenem].
Doripenem is a new member of the carbapenem family. Its spectrum is a little wider than meropenem and it is active on some Pseudomonas aeruginosa strains resistant to other carbapenems and on Burkholderia cepacia. Doripenem was evaluated in nosocomial pneumonia including ventilator-acquired pneumonia, complicated intra-abdominal infection, and complicated urinary tract infection. In nosocomial pneumonia, doripenem showed an interesting activity in P. aeruginosa infected patients. This data, along with the global increase in multiresistance, may be an opportunity to optimize our therapeutic options with a new molecule.
Guery
B-P
BP
Service de gestion du risque infectieux et des vigilances, hôpital Calmette, pavillon Christiaens, Lille cedex, France. bguery@invivo.edu
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D016956:Burkholderia cepacia / Q000187:drug effects; D015780:Carbapenems / Q000009:adverse effects / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000188:drug therapy; D000077726:Doripenem; D004353:Drug Evaluation, Preclinical; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced; D010538:Peritonitis / Q000188:drug therapy; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem